Douglas Denham
About
Douglas Denham is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Nephrology.
According to data from OpenAlex, Douglas Denham has authored 22 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Endocrinology, Diabetes and Metabolism, 12 papers in Surgery and 6 papers in Nephrology. Recurrent topics in Douglas Denham's work include Diabetes Management and Research (8 papers), Thyroid and Parathyroid Surgery (6 papers) and Parathyroid Disorders and Treatments (6 papers). Douglas Denham is often cited by papers focused on Diabetes Management and Research (8 papers), Thyroid and Parathyroid Surgery (6 papers) and Parathyroid Disorders and Treatments (6 papers). Douglas Denham collaborates with scholars based in United States, France and Romania. Douglas Denham's co-authors include Mark P. Christiansen, Bruce W. Bode, Timothy S. Bailey, Ronald Brazg, Anna Chang, Julio Rosenstock, Leslie J. Klaff, George Atiee, Carol J. Levy and Lynne Kelley and has published in prestigious journals such as Nature Medicine, The Journal of Clinical Endocrinology & Metabolism and Diabetes Care.
In The Last Decade
Douglas Denham
20 papers receiving 518 citations
Peers
Douglas Denham
Simmi Dube United States
Philippe Primo Caimmi Italy
Hao Qian China
Kaoru Nomura Japan
Lynley K. Lewis New Zealand
Huili Wei China
Hanne M. M. Rooijackers Netherlands
A Gressner Germany
Leonard Doberne United States
Andrea L. McConico United States
Citations per year, relative to Douglas Denham Douglas Denham (= 1×)
peers
Simmi Dube
Countries citing papers authored by Douglas Denham
Since
Specialization
Citations
This map shows the geographic impact of Douglas Denham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Denham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Denham more than expected).
Fields of papers citing papers by Douglas Denham
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Douglas Denham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Denham. The network helps show where Douglas Denham may publish in the future.
Co-authorship network of co-authors of Douglas Denham
This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Denham. A scholar is included among the top collaborators of Douglas Denham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Denham. Douglas Denham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bailey, Timothy S., David R. Liljenquist, Douglas Denham, et al.. (2025). Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study. Diabetes Technology & Therapeutics. 27(5). 407–411.
2.
Christofides, Elena A., Andrzej Stankiewicz, Douglas Denham, et al.. (2024). Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment. Endocrine Practice. 30(9). 810–816.
3.
Watts, Nelson B., John P. Bilezikian, Henry G. Bone, et al.. (2023). Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism. Journal of the Endocrine Society. 7(5). bvad043–bvad043.
4.
Pettus, Jeremy, Schafer Boeder, Mark P. Christiansen, et al.. (2022). Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nature Medicine. 28(10). 2092–2099.
5.
Lawitz, Eric, Rohit Loomba, Douglas Denham, et al.. (2022). TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study. Journal of Hepatology. 77. S715–S716.
6.
Ratziu, Vlad, Mary E. Rinella, Brent A. Neuschwander‐Tetri, et al.. (2021). EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. Journal of Hepatology. 76(3). 506–517.
7.
Garg, Satish K., David R. Liljenquist, Bruce W. Bode, et al.. (2021). Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics. 24(2). 84–92.
8.
Garg, Satish K., David R. Liljenquist, Bruce W. Bode, et al.. (2021). 149-OR: Evaluation of the Next Generation 180-Day Long-Term Implantable Eversense CGM System: PROMISE Study. Diabetes. 70(Supplement_1).
9.
Pettus, Jeremy, Schafer Boeder, Mark P. Christiansen, et al.. (2021). 236-OR: Volagidemab, a Human Glucagon Receptor Antagonist, Improves Glycemic Control in Subjects with Type 1 Diabetes (T1D): A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes. 70(Supplement_1).
10.
Siddiqui, Mohammad Shadab, Michael O. Idowu, Dhruvanshu Parmar, et al.. (2020). A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology. 19(12). 2670–2672.
11.
Ratziu, Vlad, Mary E. Rinella, Brent Tetri, et al.. (2020). EDP-305, a non-bile acid farnesoid X receptor (FXR) agonist, showed statistically significant improvements in liver biochemistry and hepatic steatosis in the phase 2a argon-1 study. Journal of Hepatology. 73. S56–S57.
12.
Mannstadt, Michael, B.L. Clarke, John P. Bilezikian, et al.. (2019). Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. The Journal of Clinical Endocrinology & Metabolism. 104(11). 5136–5147.
13.
Christiansen, Mark, Timothy S. Bailey, Leslie J. Klaff, et al.. (2019). Abstract #300 Evaluation of the Accuracy of an Implantable CGM System with an Updated Glucose Calculation Algorithm. Endocrine Practice. 25. 125–125.
14.
Bilezikian, John P., Henry G. Bone, B.L. Clarke, et al.. (2019). OR30-1 Safety and Efficacy of Recombinant Human Parathyroid Hormone 1-84 for the Treatment of Adults with Chronic Hypoparathyroidism: Six-Year Results of the RACE Study. Journal of the Endocrine Society. 3(Supplement_1).
15.
Clarke, B.L., Dolores Shoback, John P. Bilezikian, et al.. (2018). Five-year efficacy and safety of recombinant human parathyroid hormone 1-84 (rhPTH[1-84]) for the treatment of adults with chronic hypoparathyroidism: analysis from the open-label race study. Endocrine Abstracts.
16.
Christiansen, Mark P., Leslie J. Klaff, Ronald Brazg, et al.. (2018). A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. Diabetes Technology & Therapeutics. 20(3). 197–206.
17.
Henry, Robert R., Julio Rosenstock, Douglas Denham, et al.. (2018). Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study. Diabetes Care. 41(3). 613–619.
18.
Denney, William S., Douglas Denham, Michael R. Riggs, & Neeta B. Amin. (2016). Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF‐04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin—A Randomized, Crossover, Active‐Controlled Study. Clinical Pharmacology in Drug Development. 5(6). 517–527.
19.
Clarke, B.L., Michael Mannstadt, Tamara Vokes, et al.. (2015). Three-year safety and efficacy data for recombinant human parathyroid hormone, rhPTH(1-84), in the treatment of adults with hypoparathyroidism: the RACE study. Endocrine Abstracts.
20.
Fonseca, Vivian, Lawrence A. Lavery, Tina K. Thethi, et al.. (2012). Metanx in Type 2 Diabetes with Peripheral Neuropathy: A Randomized Trial. The American Journal of Medicine. 126(2). 141–149.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Simmi Dube Breakdown of academic impact, for papers by Philippe Primo Caimmi Breakdown of academic impact, for papers by Hao Qian Breakdown of academic impact, for papers by Kaoru Nomura Breakdown of academic impact, for papers by Lynley K. Lewis Breakdown of academic impact, for papers by Huili Wei Breakdown of academic impact, for papers by Hanne M. M. Rooijackers Breakdown of academic impact, for papers by A Gressner Breakdown of academic impact, for papers by Leonard Doberne Breakdown of academic impact, for papers by Andrea L. McConico